<p>The new facility, Abbott Biotechnology Limited (ABL), received FDA approval in February to commercially produce Humira for the US market. The new plant is Abbott's single-largest capital investment to date, costing approximately $450 million. <br /><br />This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing, said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.<br /><br />ABL is now the main production facility for Humira, the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in the US and Europe. The drug is also approved in the US to treat Crohn's disease. <br /><br />This new plant has significantly more production capacity than the other manufacturing facility for Humira, the Abbott Bioresearch Center (ABC). The ABC site will now serve as a supporting production facility for Humira and will focus on Abbott's growing biologics R&D portfolio.</p>